Treatment Options for Patients with CLL Progressing on Covalent BTK Inhibitors
Dr. Hill and Dr. Gia discuss treatment options for patients who progress on covalent and noncovalent BTK inhibitors.
Molecular Mechanisms of Resistance to Acalabrutinib in CLL
Exploring molecular mechanisms of resistance to BTK inhibitors as well as emergent data concerning how this resistance might be overcome.
Clinical Considerations for BTK Inhibitor Treatment Selection
Dr. Hill and Dr. Gia share how varying risk profiles of different BTK inhibitors may impact patient outcomes, along with relevant real-world data.
Comparing BTK Inhibitors: Key Findings from Head-to-Head Trials
An insightful analysis of head-to-head trials comparing BTK inhibitors (acalabrutinib vs ibrutinib and zanubrutinib vs ibrutinib) to guide treatment selection in CLL.
Covalent BTK Inhibitors in Relapsed/Refractory CLL
Subject-matter experts review treatment options for patients with relapsed/refractory CLL.
Mechanism and Frontline Use of BTK Inhibitors in CLL
Brian T. Hill, MD, Ph.D., and Paulo Gia, MD explain the mechanism of action of BTK inhibitors and the rationale behind their use in chronic lymphocytic leukemia (CLL).
Closing Remarks on Unmet Needs in R/R FL
Dr Hill closes by discussing current unmet needs in the R/R FL landscape and giving practical advice to providers caring for patients with FL.
CAR T-cell Options for Patients with R/R FL
A focused discussion on available CAR T-cell therapies for patients with R/R FL, supporting efficacy data, and how these therapies have impacted the field.
Considerations for Treatment Selection in the Third-Line R/R FL Setting
Dr Hill shares how he would have handled the patient case and discusses factors that contribute to treatment selection among third-line therapies for patients with R/R FL, including axicabtagene ciloleucel and other CAR T-cell therapies.
Typical Treatment Responses in Patients with FL and Incidence of Relapsed or Refractory Disease
Insights concerning typical treatment responses experienced by patients with FL, clinical factors that may be predictive of response, and the incidence of relapsed or refractory disease.
First-, Second-, and Third-Line Treatment Selection for a FL Patient Case
Dr Hill continues his discussion of the case, outlining the first-, second, and third-line treatment strategies employed for this particular patient.
Follicular Lymphoma Background and Introduction to a Patient Case
Brian T. Hill, MD, PhD briefly reviews the diagnosis and staging of FL, typical prognoses for patients with the disease, and begins to outline a patient case of R/R FL.
Clinical Pearls in the Management of Marginal Zone Lymphoma
Closing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.
Novel Treatment Strategies for Relapsed/Refractory MZL
A comprehensive review of novel therapies in relapsed/refractory marginal zone lymphoma and possible sequencing strategies in this setting.
Frontline Treatment Options for Marginal Zone Lymphoma
Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.
Clinical Pearls in the Management of Follicular Lymphoma
Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.
Optimizing the Sequencing of Therapy in Follicular Lymphoma
Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.
PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma
A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.
Dr. Hill on the Potential Utility of Next-Generation PI3K Inhibitors in CLL
Brian T. Hill, MD, PhD, discusses the potential utility of next-generation PI3K inhibitors in chronic lymphocytic leukemia.
Novel Therapies and Treatment Selection in Patients With Relapsed/Refractory FL
Expert perspectives on novel approaches to treatment in the relapsed/refractory setting, particularly CAR T-cell therapy, for patients with follicular lymphoma.
Pathophysiology of Follicular Lymphoma and Frontline Therapy
Shared insight on the indolent nature of follicular lymphoma and frontline therapy options for this disease.
Clinical Pearls in the Management of Mantle Cell Lymphoma
Closing out their discussion on mantle cell lymphoma, expert panelists share clinical pearls for practicing community physicians.
Optimizing MCL Management: Sequencing and Combination Strategies
Panelists use an illustrative clinical case to highlight best practices in sequencing therapy for mantle cell lymphoma and discuss novel combination strategies under investigation.
CAR T-cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma
A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Second-Line Therapy for MCL: Differentiating Available BTK Inhibitors
Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.
Considerations for Selection and Use of Frontline Therapy in Mantle Cell Lymphoma
Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.
An Overview of Mantle Cell Lymphoma and Frontline Therapy
Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.
Dr. Hill on the Utility of BTK Inhibitors in Relapsed/Refractory MCL
Brian T. Hill, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Dr. Hill on the Approval of Brexucabtagene Autoleucel in MCL
Brian T. Hill, MD, PhD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.
Dr. Hill on Next Steps for Research Exploring CAR T-Cell Therapy in MCL
Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512